ArticleCase reports in hepatology2025
A Case of Evolving Hepatotoxicity Following Systemic Drug Reaction to Isoniazid-Rifapentine (3HP).
Article in Case reports in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 3-month, once-weekly regimen of isoniazid plus rifapentine (3HP) is widely used for latent tuberculosis infection (LTBI) because of its shorter duration and favorable adherence compared to isoniazid monotherapy. However, 3HP is associated with hepatotoxicity as well as systemic drug reactions (SDRs), characterized by rapid-onset flu-like symptoms, fever, myalgias, and rash, which may complicate therapy. We describe a healthy 26-year-old male diagnosed with latent tuberculosis who developed acute SDR symptoms accompanied by hepatotoxicity after his third dose of 3HP. The liver injury was initially cholestatic and evolved into a worsening hepatocellular pattern despite discontinuation of 3HP, with gradual normalization over 4 weeks. Autoimmune serologies were briefly positive but resolved spontaneously without intervention. This case illustrates the potential for SDRs with evolving liver injury during 3HP therapy and underscores the importance of early recognition of adverse effects and individualized management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.